| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes, Gestational | 49 | 2025 | 312 | 9.210 |
Why?
|
| Pregnancy | 85 | 2025 | 1466 | 4.650 |
Why?
|
| Weight Gain | 16 | 2023 | 156 | 4.190 |
Why?
|
| Body Mass Index | 24 | 2025 | 937 | 3.270 |
Why?
|
| Overweight | 11 | 2025 | 266 | 3.230 |
Why?
|
| Pregnancy Complications | 13 | 2024 | 197 | 2.960 |
Why?
|
| Female | 110 | 2025 | 12444 | 2.880 |
Why?
|
| Exercise | 14 | 2025 | 513 | 2.680 |
Why?
|
| Obesity | 16 | 2025 | 814 | 2.650 |
Why?
|
| Humans | 116 | 2025 | 17376 | 2.580 |
Why?
|
| Adult | 77 | 2025 | 7529 | 2.380 |
Why?
|
| Diabetes Mellitus, Type 2 | 19 | 2022 | 666 | 2.070 |
Why?
|
| Premature Birth | 5 | 2023 | 132 | 2.000 |
Why?
|
| Leiomyoma | 3 | 2025 | 13 | 1.880 |
Why?
|
| Cohort Studies | 30 | 2025 | 2526 | 1.800 |
Why?
|
| Pediatric Obesity | 7 | 2024 | 86 | 1.770 |
Why?
|
| Ethnic Groups | 10 | 2021 | 456 | 1.690 |
Why?
|
| Prenatal Care | 11 | 2024 | 127 | 1.670 |
Why?
|
| Dermatitis, Atopic | 2 | 2023 | 15 | 1.600 |
Why?
|
| Hypertension, Pregnancy-Induced | 4 | 2025 | 39 | 1.550 |
Why?
|
| Infant, Newborn | 22 | 2024 | 805 | 1.440 |
Why?
|
| Delivery of Health Care, Integrated | 5 | 2025 | 537 | 1.410 |
Why?
|
| Cesarean Section | 3 | 2021 | 33 | 1.390 |
Why?
|
| Bariatric Surgery | 2 | 2023 | 131 | 1.390 |
Why?
|
| Risk Factors | 29 | 2025 | 3255 | 1.370 |
Why?
|
| Taxes | 3 | 2025 | 24 | 1.350 |
Why?
|
| Depression | 7 | 2023 | 487 | 1.310 |
Why?
|
| California | 32 | 2025 | 2317 | 1.310 |
Why?
|
| Pregnancy Outcome | 10 | 2025 | 158 | 1.310 |
Why?
|
| Hypertension | 4 | 2025 | 469 | 1.290 |
Why?
|
| Prenatal Exposure Delayed Effects | 7 | 2025 | 168 | 1.270 |
Why?
|
| Young Adult | 28 | 2025 | 2473 | 1.190 |
Why?
|
| Life Style | 12 | 2025 | 316 | 1.160 |
Why?
|
| Telemedicine | 4 | 2024 | 182 | 1.090 |
Why?
|
| Blood Glucose | 16 | 2019 | 315 | 1.070 |
Why?
|
| Pregnancy Trimesters | 2 | 2016 | 29 | 1.040 |
Why?
|
| Postpartum Period | 8 | 2025 | 79 | 1.020 |
Why?
|
| Child Development | 3 | 2024 | 53 | 1.020 |
Why?
|
| Cardiovascular Diseases | 2 | 2024 | 533 | 1.010 |
Why?
|
| Insulin Resistance | 4 | 2014 | 128 | 1.010 |
Why?
|
| Pre-Eclampsia | 2 | 2023 | 40 | 0.990 |
Why?
|
| Maternal Exposure | 3 | 2025 | 66 | 0.950 |
Why?
|
| Adolescent | 25 | 2025 | 3533 | 0.940 |
Why?
|
| Mothers | 4 | 2021 | 103 | 0.910 |
Why?
|
| Mobile Applications | 1 | 2024 | 14 | 0.910 |
Why?
|
| Sex Hormone-Binding Globulin | 2 | 2014 | 21 | 0.890 |
Why?
|
| Middle Aged | 34 | 2025 | 7885 | 0.840 |
Why?
|
| Diet | 4 | 2024 | 356 | 0.830 |
Why?
|
| Hypoglycemic Agents | 9 | 2022 | 251 | 0.800 |
Why?
|
| Venous Thrombosis | 1 | 2022 | 21 | 0.790 |
Why?
|
| Gestational Age | 5 | 2023 | 112 | 0.790 |
Why?
|
| Triglycerides | 2 | 2021 | 83 | 0.780 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 56 | 0.780 |
Why?
|
| Pulmonary Embolism | 1 | 2022 | 44 | 0.780 |
Why?
|
| Skin Neoplasms | 1 | 2023 | 58 | 0.770 |
Why?
|
| Glyburide | 1 | 2022 | 7 | 0.760 |
Why?
|
| Vitamin D | 1 | 2022 | 72 | 0.750 |
Why?
|
| Longitudinal Studies | 13 | 2025 | 677 | 0.720 |
Why?
|
| Weight Reduction Programs | 2 | 2019 | 49 | 0.700 |
Why?
|
| Cholesterol, HDL | 1 | 2021 | 69 | 0.690 |
Why?
|
| Child, Preschool | 12 | 2025 | 1375 | 0.690 |
Why?
|
| Case-Control Studies | 11 | 2025 | 1100 | 0.690 |
Why?
|
| Odds Ratio | 12 | 2016 | 644 | 0.690 |
Why?
|
| Prospective Studies | 15 | 2025 | 1229 | 0.660 |
Why?
|
| Child | 17 | 2025 | 2382 | 0.660 |
Why?
|
| Male | 27 | 2025 | 9843 | 0.650 |
Why?
|
| Breast Neoplasms | 4 | 2023 | 977 | 0.650 |
Why?
|
| Weight Loss | 7 | 2025 | 295 | 0.650 |
Why?
|
| Metformin | 5 | 2018 | 50 | 0.630 |
Why?
|
| Retrospective Studies | 9 | 2025 | 2428 | 0.630 |
Why?
|
| Pain Management | 1 | 2019 | 53 | 0.630 |
Why?
|
| Infant | 11 | 2024 | 1162 | 0.590 |
Why?
|
| Stress, Psychological | 3 | 2022 | 133 | 0.580 |
Why?
|
| Precision Medicine | 1 | 2018 | 28 | 0.570 |
Why?
|
| Quality Improvement | 1 | 2019 | 190 | 0.560 |
Why?
|
| Analgesics, Opioid | 2 | 2023 | 246 | 0.560 |
Why?
|
| Hispanic Americans | 7 | 2021 | 378 | 0.560 |
Why?
|
| Fetal Macrosomia | 5 | 2017 | 27 | 0.520 |
Why?
|
| Lipids | 1 | 2016 | 69 | 0.500 |
Why?
|
| Continental Population Groups | 4 | 2016 | 289 | 0.490 |
Why?
|
| Residence Characteristics | 4 | 2025 | 253 | 0.490 |
Why?
|
| Dyslipidemias | 1 | 2016 | 56 | 0.480 |
Why?
|
| Glucose Tolerance Test | 9 | 2022 | 107 | 0.470 |
Why?
|
| Pandemics | 5 | 2023 | 285 | 0.460 |
Why?
|
| Logistic Models | 10 | 2016 | 884 | 0.460 |
Why?
|
| Liver | 1 | 2014 | 34 | 0.440 |
Why?
|
| Self Report | 1 | 2016 | 257 | 0.440 |
Why?
|
| Adiponectin | 1 | 2013 | 21 | 0.420 |
Why?
|
| Electronic Health Records | 2 | 2018 | 707 | 0.420 |
Why?
|
| Cross-Sectional Studies | 9 | 2022 | 1287 | 0.420 |
Why?
|
| Pharmacogenomic Variants | 3 | 2018 | 7 | 0.410 |
Why?
|
| Biomarkers | 6 | 2024 | 306 | 0.410 |
Why?
|
| Motivational Interviewing | 2 | 2024 | 34 | 0.410 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2018 | 363 | 0.400 |
Why?
|
| Vitamins | 2 | 2022 | 59 | 0.390 |
Why?
|
| Prehypertension | 1 | 2012 | 21 | 0.380 |
Why?
|
| Inflammation | 1 | 2012 | 63 | 0.380 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2023 | 5 | 0.370 |
Why?
|
| Autism Spectrum Disorder | 2 | 2024 | 159 | 0.360 |
Why?
|
| Risk Reduction Behavior | 4 | 2020 | 104 | 0.360 |
Why?
|
| Women's Health | 2 | 2023 | 197 | 0.350 |
Why?
|
| Blood Pressure | 3 | 2025 | 275 | 0.340 |
Why?
|
| United States | 11 | 2025 | 3891 | 0.340 |
Why?
|
| Risk | 4 | 2014 | 498 | 0.340 |
Why?
|
| Prenatal Diagnosis | 1 | 2010 | 17 | 0.330 |
Why?
|
| Glucose Intolerance | 4 | 2015 | 43 | 0.320 |
Why?
|
| Hypoglycemia | 2 | 2006 | 46 | 0.320 |
Why?
|
| Complementary Therapies | 3 | 2004 | 41 | 0.320 |
Why?
|
| Thiazolidinediones | 3 | 2015 | 50 | 0.310 |
Why?
|
| Lactation | 2 | 2024 | 34 | 0.310 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2015 | 58 | 0.300 |
Why?
|
| Insulin | 3 | 2022 | 190 | 0.290 |
Why?
|
| Breast Feeding | 4 | 2014 | 113 | 0.290 |
Why?
|
| Poverty | 3 | 2025 | 165 | 0.290 |
Why?
|
| Surveys and Questionnaires | 6 | 2017 | 1287 | 0.290 |
Why?
|
| Pregnancy Trimester, First | 3 | 2020 | 41 | 0.290 |
Why?
|
| Preconception Care | 2 | 2021 | 40 | 0.290 |
Why?
|
| Health Behavior | 5 | 2025 | 345 | 0.280 |
Why?
|
| Dietary Supplements | 3 | 2004 | 84 | 0.280 |
Why?
|
| Treatment Outcome | 6 | 2023 | 1170 | 0.280 |
Why?
|
| Environmental Pollutants | 2 | 2025 | 53 | 0.280 |
Why?
|
| Prevalence | 7 | 2019 | 839 | 0.280 |
Why?
|
| European Continental Ancestry Group | 6 | 2016 | 480 | 0.280 |
Why?
|
| Patient Education as Topic | 4 | 2024 | 193 | 0.270 |
Why?
|
| Social Class | 3 | 2025 | 117 | 0.270 |
Why?
|
| Contraceptives, Oral, Hormonal | 1 | 2007 | 12 | 0.270 |
Why?
|
| Androgens | 1 | 2007 | 14 | 0.270 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2024 | 54 | 0.270 |
Why?
|
| Hyperbilirubinemia, Neonatal | 1 | 2006 | 17 | 0.260 |
Why?
|
| Accelerometry | 2 | 2025 | 51 | 0.250 |
Why?
|
| Sleep | 2 | 2025 | 57 | 0.250 |
Why?
|
| Aged | 10 | 2025 | 6129 | 0.240 |
Why?
|
| Parabens | 1 | 2025 | 4 | 0.240 |
Why?
|
| Memory Disorders | 1 | 2025 | 8 | 0.240 |
Why?
|
| Memory, Episodic | 1 | 2025 | 6 | 0.240 |
Why?
|
| Uterine Neoplasms | 1 | 2025 | 13 | 0.240 |
Why?
|
| Healthy Lifestyle | 1 | 2025 | 16 | 0.230 |
Why?
|
| Databases, Factual | 3 | 2019 | 306 | 0.230 |
Why?
|
| Organophosphates | 1 | 2024 | 11 | 0.230 |
Why?
|
| Flame Retardants | 1 | 2024 | 14 | 0.230 |
Why?
|
| Internal-External Control | 1 | 2004 | 11 | 0.230 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 538 | 0.230 |
Why?
|
| Food Supply | 1 | 2024 | 39 | 0.220 |
Why?
|
| Maternal Nutritional Physiological Phenomena | 2 | 2024 | 10 | 0.220 |
Why?
|
| Motivation | 1 | 2025 | 116 | 0.220 |
Why?
|
| Cognitive Dysfunction | 1 | 2025 | 54 | 0.220 |
Why?
|
| Neoplasms | 4 | 2015 | 448 | 0.220 |
Why?
|
| Social Segregation | 1 | 2023 | 2 | 0.220 |
Why?
|
| Obstetric Labor, Premature | 1 | 2003 | 8 | 0.210 |
Why?
|
| Menopause | 2 | 2021 | 68 | 0.210 |
Why?
|
| Child Health | 2 | 2024 | 39 | 0.210 |
Why?
|
| Prediabetic State | 1 | 2024 | 52 | 0.210 |
Why?
|
| Hypersensitivity | 1 | 2003 | 18 | 0.210 |
Why?
|
| Eclampsia | 1 | 2023 | 12 | 0.210 |
Why?
|
| Fruit | 2 | 2020 | 80 | 0.210 |
Why?
|
| Glycated Hemoglobin A | 4 | 2017 | 184 | 0.210 |
Why?
|
| Ideal Body Weight | 2 | 2020 | 10 | 0.210 |
Why?
|
| Vegetables | 2 | 2020 | 88 | 0.210 |
Why?
|
| Control Groups | 1 | 2023 | 2 | 0.210 |
Why?
|
| Diabetes Mellitus | 3 | 2024 | 455 | 0.210 |
Why?
|
| Health Status | 2 | 2004 | 295 | 0.200 |
Why?
|
| Fetal Growth Retardation | 1 | 2023 | 11 | 0.200 |
Why?
|
| Glucose | 1 | 2023 | 31 | 0.200 |
Why?
|
| Communicable Disease Control | 1 | 2023 | 19 | 0.200 |
Why?
|
| Triclosan | 1 | 2022 | 4 | 0.200 |
Why?
|
| Folic Acid | 1 | 2022 | 29 | 0.200 |
Why?
|
| Attitude to Health | 4 | 2017 | 148 | 0.200 |
Why?
|
| Antihypertensive Agents | 1 | 2024 | 155 | 0.200 |
Why?
|
| Depression, Postpartum | 1 | 2022 | 22 | 0.190 |
Why?
|
| Cholesterol | 2 | 2012 | 82 | 0.190 |
Why?
|
| Alcohol Drinking | 2 | 2020 | 355 | 0.190 |
Why?
|
| Autistic Disorder | 1 | 2023 | 100 | 0.190 |
Why?
|
| Prostatic Neoplasms | 3 | 2015 | 263 | 0.180 |
Why?
|
| Confidence Intervals | 2 | 2016 | 231 | 0.180 |
Why?
|
| Cannabis | 1 | 2023 | 85 | 0.180 |
Why?
|
| Severity of Illness Index | 1 | 2023 | 439 | 0.180 |
Why?
|
| Maternal Age | 1 | 2021 | 74 | 0.170 |
Why?
|
| Cluster Analysis | 2 | 2018 | 86 | 0.170 |
Why?
|
| Referral and Consultation | 2 | 2012 | 160 | 0.170 |
Why?
|
| Research Design | 3 | 2019 | 343 | 0.170 |
Why?
|
| Cholesterol, LDL | 1 | 2021 | 112 | 0.170 |
Why?
|
| Organic Cation Transport Proteins | 2 | 2017 | 3 | 0.170 |
Why?
|
| Incidence | 3 | 2013 | 1266 | 0.160 |
Why?
|
| Energy Intake | 1 | 2020 | 98 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2019 | 16 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 35 | 0.160 |
Why?
|
| Developmental Disabilities | 1 | 2019 | 52 | 0.150 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 609 | 0.150 |
Why?
|
| Program Evaluation | 1 | 2019 | 215 | 0.150 |
Why?
|
| Carboxypeptidases A | 1 | 2018 | 1 | 0.150 |
Why?
|
| Asian Americans | 3 | 2016 | 164 | 0.150 |
Why?
|
| Eye Proteins | 1 | 2018 | 16 | 0.150 |
Why?
|
| Health Status Disparities | 2 | 2016 | 148 | 0.140 |
Why?
|
| Fasting | 2 | 2014 | 46 | 0.140 |
Why?
|
| Pregnancy Trimester, Second | 2 | 2010 | 26 | 0.140 |
Why?
|
| Membrane Transport Proteins | 1 | 2017 | 4 | 0.140 |
Why?
|
| Washington | 5 | 2004 | 385 | 0.130 |
Why?
|
| Behavior Therapy | 2 | 2015 | 126 | 0.130 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Quantitative Trait, Heritable | 1 | 2016 | 7 | 0.130 |
Why?
|
| Environment | 1 | 2016 | 50 | 0.130 |
Why?
|
| Pregnancy in Diabetics | 1 | 2016 | 17 | 0.130 |
Why?
|
| Delivery, Obstetric | 1 | 2016 | 18 | 0.130 |
Why?
|
| Membrane Proteins | 1 | 2016 | 38 | 0.130 |
Why?
|
| Lipoproteins, HDL | 1 | 2016 | 5 | 0.130 |
Why?
|
| Lipoproteins, LDL | 1 | 2016 | 12 | 0.130 |
Why?
|
| African Americans | 3 | 2016 | 443 | 0.130 |
Why?
|
| Mexican Americans | 2 | 2013 | 42 | 0.120 |
Why?
|
| Postnatal Care | 2 | 2014 | 20 | 0.120 |
Why?
|
| Waist Circumference | 2 | 2013 | 33 | 0.120 |
Why?
|
| Exercise Therapy | 1 | 2016 | 72 | 0.120 |
Why?
|
| Disease Progression | 1 | 2016 | 259 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2016 | 118 | 0.120 |
Why?
|
| Managed Care Programs | 1 | 2016 | 309 | 0.120 |
Why?
|
| Language | 1 | 2015 | 48 | 0.110 |
Why?
|
| Pharmacogenetics | 1 | 2014 | 12 | 0.110 |
Why?
|
| Transcription Factors | 1 | 2014 | 19 | 0.110 |
Why?
|
| Proteinuria | 1 | 2014 | 25 | 0.110 |
Why?
|
| Early Diagnosis | 1 | 2014 | 36 | 0.110 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 395 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2015 | 69 | 0.110 |
Why?
|
| Social Identification | 1 | 2013 | 6 | 0.110 |
Why?
|
| Patient Selection | 1 | 2015 | 178 | 0.110 |
Why?
|
| Aged, 80 and over | 5 | 2017 | 1942 | 0.100 |
Why?
|
| Time Factors | 2 | 2008 | 1044 | 0.100 |
Why?
|
| Educational Status | 4 | 2023 | 179 | 0.100 |
Why?
|
| Sex Ratio | 1 | 2012 | 2 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2012 | 23 | 0.100 |
Why?
|
| Blood Pressure Determination | 1 | 2012 | 52 | 0.100 |
Why?
|
| Prognosis | 1 | 2013 | 604 | 0.090 |
Why?
|
| Body Weight | 2 | 2025 | 203 | 0.090 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2011 | 22 | 0.090 |
Why?
|
| Feeding Behavior | 2 | 2003 | 163 | 0.090 |
Why?
|
| Health Promotion | 1 | 2014 | 278 | 0.090 |
Why?
|
| Genome-Wide Association Study | 3 | 2018 | 248 | 0.090 |
Why?
|
| Anxiety | 2 | 2022 | 154 | 0.090 |
Why?
|
| Health Services | 1 | 2001 | 112 | 0.090 |
Why?
|
| Follow-Up Studies | 4 | 2020 | 1155 | 0.090 |
Why?
|
| Patient Satisfaction | 3 | 2004 | 198 | 0.070 |
Why?
|
| Alcohol-Related Disorders | 1 | 2009 | 48 | 0.070 |
Why?
|
| Alcoholism | 1 | 2001 | 337 | 0.070 |
Why?
|
| Ethinyl Estradiol | 1 | 2007 | 4 | 0.070 |
Why?
|
| Organic Cation Transporter 2 | 2 | 2017 | 3 | 0.070 |
Why?
|
| Hyperbilirubinemia | 1 | 2006 | 9 | 0.070 |
Why?
|
| Parity | 2 | 2020 | 57 | 0.070 |
Why?
|
| Age Distribution | 2 | 2004 | 239 | 0.060 |
Why?
|
| Quality of Life | 3 | 2004 | 505 | 0.060 |
Why?
|
| Phenotype | 2 | 2017 | 148 | 0.060 |
Why?
|
| Neuropsychological Tests | 1 | 2025 | 43 | 0.060 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 1 | 2024 | 4 | 0.060 |
Why?
|
| Esters | 1 | 2024 | 7 | 0.060 |
Why?
|
| Linear Models | 2 | 2016 | 210 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2004 | 366 | 0.060 |
Why?
|
| Cities | 1 | 2024 | 30 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2004 | 180 | 0.060 |
Why?
|
| Censuses | 1 | 2023 | 29 | 0.050 |
Why?
|
| Tobacco | 1 | 2023 | 11 | 0.050 |
Why?
|
| Stillbirth | 1 | 2023 | 29 | 0.050 |
Why?
|
| Ethanol | 1 | 2023 | 21 | 0.050 |
Why?
|
| Directive Counseling | 2 | 2014 | 23 | 0.050 |
Why?
|
| Phenol | 1 | 2022 | 4 | 0.050 |
Why?
|
| Benzhydryl Compounds | 1 | 2022 | 26 | 0.050 |
Why?
|
| Bayes Theorem | 1 | 2022 | 73 | 0.050 |
Why?
|
| Phenols | 1 | 2022 | 37 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2014 | 211 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2022 | 78 | 0.050 |
Why?
|
| Minority Groups | 1 | 2022 | 103 | 0.050 |
Why?
|
| Anxiety Disorders | 1 | 2022 | 92 | 0.050 |
Why?
|
| Colonic Neoplasms | 1 | 2002 | 163 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2001 | 89 | 0.040 |
Why?
|
| Vasomotor System | 1 | 2020 | 4 | 0.040 |
Why?
|
| Sweating | 1 | 2020 | 8 | 0.040 |
Why?
|
| Motor Activity | 2 | 2014 | 208 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2004 | 380 | 0.040 |
Why?
|
| Hot Flashes | 1 | 2020 | 38 | 0.040 |
Why?
|
| Child Health Services | 1 | 2001 | 106 | 0.040 |
Why?
|
| Mental Health | 1 | 2022 | 168 | 0.040 |
Why?
|
| Likelihood Functions | 1 | 2020 | 45 | 0.040 |
Why?
|
| Thinness | 1 | 2020 | 31 | 0.040 |
Why?
|
| Intelligence | 1 | 2019 | 9 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2018 | 4 | 0.040 |
Why?
|
| Double-Blind Method | 1 | 2018 | 142 | 0.040 |
Why?
|
| Telephone | 2 | 2014 | 150 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2019 | 316 | 0.040 |
Why?
|
| Hospitalization | 1 | 2023 | 805 | 0.040 |
Why?
|
| Counseling | 1 | 2019 | 173 | 0.030 |
Why?
|
| Maternal Behavior | 1 | 2017 | 12 | 0.030 |
Why?
|
| Octamer Transcription Factor-1 | 1 | 2017 | 1 | 0.030 |
Why?
|
| Sports | 1 | 2017 | 22 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 7 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2003 | 627 | 0.030 |
Why?
|
| Social Environment | 1 | 2017 | 85 | 0.030 |
Why?
|
| Genotype | 1 | 2017 | 223 | 0.030 |
Why?
|
| Asian Continental Ancestry Group | 1 | 2016 | 87 | 0.030 |
Why?
|
| African Continental Ancestry Group | 1 | 2016 | 144 | 0.030 |
Why?
|
| Sp1 Transcription Factor | 1 | 2014 | 1 | 0.030 |
Why?
|
| PPAR alpha | 1 | 2014 | 1 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 4 | 1 | 2014 | 4 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 13 | 0.030 |
Why?
|
| Models, Biological | 1 | 2014 | 28 | 0.030 |
Why?
|
| Homeostasis | 1 | 2014 | 11 | 0.030 |
Why?
|
| Cross-Over Studies | 1 | 2014 | 47 | 0.030 |
Why?
|
| Confounding Factors (Epidemiology) | 1 | 2014 | 84 | 0.030 |
Why?
|
| Psychometrics | 1 | 2013 | 119 | 0.030 |
Why?
|
| Body Composition | 1 | 2013 | 91 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2013 | 367 | 0.020 |
Why?
|
| Infant, Low Birth Weight | 1 | 2012 | 29 | 0.020 |
Why?
|
| Bottle Feeding | 1 | 2011 | 7 | 0.020 |
Why?
|
| Utilization Review | 1 | 2001 | 44 | 0.020 |
Why?
|
| Patient Admission | 1 | 2001 | 69 | 0.020 |
Why?
|
| Algorithms | 1 | 2013 | 226 | 0.020 |
Why?
|
| Length of Stay | 1 | 2001 | 171 | 0.020 |
Why?
|
| Recurrence | 1 | 2011 | 165 | 0.020 |
Why?
|
| Mass Screening | 2 | 2009 | 671 | 0.020 |
Why?
|
| Sex Factors | 2 | 2003 | 607 | 0.020 |
Why?
|
| Registries | 1 | 2012 | 460 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2006 | 8 | 0.020 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2006 | 34 | 0.020 |
Why?
|
| Personal Autonomy | 1 | 2003 | 5 | 0.010 |
Why?
|
| Income | 1 | 2002 | 87 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2003 | 304 | 0.010 |
Why?
|
| Food Labeling | 1 | 2001 | 3 | 0.010 |
Why?
|
| SEER Program | 1 | 2001 | 94 | 0.010 |
Why?
|
| Diet Surveys | 1 | 2001 | 56 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2001 | 280 | 0.010 |
Why?
|
| Age Factors | 1 | 2003 | 884 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2001 | 254 | 0.010 |
Why?
|